Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial - Concepedia

Concepedia

Publication | Open Access

Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial

DOI Full Paper Access

132

Citations

18

References

2013

Year

Alfredo Carrato, Anna Świeboda-Sadlej, Marzanna Staszewska-Skurczyńska, Robert Lim, Laslo Roman, Yaroslav Shparyk, Igor Bondarenko, Derek J. Jonker, Yan Sun, Jhony A. De La Cruz‐Vargas,

Journal of Clinical Oncology

Abstract

Sunitinib 37.5 mg per day (schedule 4/2) plus FOLFIRI is not superior to FOLFIRI alone and has a poorer safety profile. This combination regimen is not recommended for previously untreated mCRC.

References

	Year	Citations

Page 1